PMID: 16519007Mar 8, 2006Paper

Assessment of GDNF in primate models of Parkinson's disease: comparison with human studies

Reviews in the Neurosciences
Andisheh Eslamboli

Abstract

Potential future treatments for Parkinson's disease (PD) include those that not only provide symptomatic relief to patients but are also neuroprotective and/or neurorestorative. Glial cell line-derived neurotrophic factor (GDNF) may be a valuable candidate in this regard. Positive results using monkeys have encouraged the use of GDNF in human trials. These trials have unfortunately shown mixed results, illustrating the influence that various parameters of administration can have on clinical outcome. The aim of this review is to compare the findings of these clinical studies with available primate data. While bolus intraventricular injections of GDNF in primates have shown some behavioural efficacy, there was no clinical benefit in the first human trial using this method, which was most likely a result of inefficient GDNF distribution in the striatal parenchyma. In primates, however, continuous (rather than bolus) delivery of GDNF into the ventricles results in significant distribution in the striatum. While chronic delivery of GDNF into the ventricles has not been assessed in humans, intraputamenal protein delivery in two Phase I trials have demonstrated that GDNF considerably reduces PD symptoms, suggesting that the putamen is...Continue Reading

References

Mar 21, 1996·Nature·D M GashG A Gerhardt
Oct 8, 1998·Brain : a Journal of Neurology·V S Ramachandran, W Hirstein
Sep 16, 1999·Journal of Neurology, Neurosurgery, and Psychiatry·D AarslandJ L Cummings
Oct 14, 2000·Journal of Neurology, Neurosurgery, and Psychiatry·K H KarlsenJ P Larsen
Feb 13, 2001·The European Journal of Neuroscience·M M IravaniP Jenner
May 2, 2003·The Journal of Comparative Neurology·Yi AiDon M Gash
Jan 30, 2004·Nature Neuroscience·Deniz KirikAnders Björklund

❮ Previous
Next ❯

Citations

Apr 18, 2008·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Milam A BrantleyJeffrey Milbrandt
Aug 1, 2006·Photomedicine and Laser Surgery
Aug 22, 2006·Expert Opinion on Biological Therapy·Kurt A SailorHongjun Song
Jan 3, 2009·Neurobiology of Disease·Jagdeep K SandhuMarianna Sikorska
Mar 28, 2008·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Naomi P VisanjiDaryl D Rees
Jan 25, 2011·The Mount Sinai Journal of Medicine, New York·Dustin R WakemanJeffrey H Kordower
Oct 18, 2006·Neurochemical Research·K S Madhusoodanan, Ferid Murad

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Astrocytes in Parkinson Disease

Parkinson's disease (PD) is a neurodegenerative disorder caused by the progressive loss of dopaminergic neurons. Some PD-genes may be associated with astrocyte dysfunction. Discover the latest research on astrocytes in Parkinson's disease here.

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.